infigratinib
qed therapeutics,helsinn
['urothelial', 'proof 301']
want to learn more about for the research we are conducting in patients suffering from #cholangiocarcinoma or #urothelialcarcinoma with fgfr genetic alterations? come and visit our booth #6025 at and hear all about the ongoing proof 301 and proof 302 trials.
#clinicaltrial
Helsinn is a fully integrated, global biopharma company focused on improving the lives of cancer patients all over the world. https://t.co/NUziRuBgtr